2017
DOI: 10.2174/1389450118666170227153940
|View full text |Cite
|
Sign up to set email alerts
|

Current Drug Targets in Obesity Pharmacotherapy – A Review

Abstract: Obesity, an impending global pandemic, is not being effectively controlled by current measures such as lifestyle modifications, bariatric surgery or available medications. Its toll on health and economy compels us to look for more effective measures. Fortunately, the advances in biology and molecular technology have been in our favour for delineating new pathways in the pathophysiology of obesity and have led to subsequent development of new drug targets. Development of antiobesity drugs has often been riddled… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
28
0
7

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 49 publications
(35 citation statements)
references
References 0 publications
0
28
0
7
Order By: Relevance
“…The medical-surgical world is increasingly oriented towards drug-or surgeon-centered treatments. Obesity is treated with anti-obesity medications or bariatric surgery, 143,144 insomnia with transcranial magnetic stimulation, 145 and treatmentresistant conditions with neurosurgical implants. 146 It seems that multiple benefits deriving from healthy diet, physical activity, and restful sleep have been progressively forgotten.…”
Section: Resultsmentioning
confidence: 99%
“…The medical-surgical world is increasingly oriented towards drug-or surgeon-centered treatments. Obesity is treated with anti-obesity medications or bariatric surgery, 143,144 insomnia with transcranial magnetic stimulation, 145 and treatmentresistant conditions with neurosurgical implants. 146 It seems that multiple benefits deriving from healthy diet, physical activity, and restful sleep have been progressively forgotten.…”
Section: Resultsmentioning
confidence: 99%
“…To date, however, there has been no approved combination agent for obesity management, besides phentermine/ topiramate and naltrexone/bupropion. Other co-administered medications have been investigated to elucidate their long-term efficacy and adverse events [15,16]. Most combinations primarily focus on both controlling hunger/appetite/satiety and inhibiting peripheral calorie absorption (i.e., phentermine/sodium glucose co-transporter 2 [SGLT-2] inhibitor, a GLP-1 agonist/other gut hormones, or an SGLT-2 inhibitor).…”
Section: Combination Of Anti-obesity Drugs In Clinical Developmentmentioning
confidence: 99%
“…Currently, most guidelines recommend pharmacotherapy as a second-line treatment for weight management after lifestyle modification [13,14]. In fact, numerous medications have been developed for the long-term management of obesity, with different mechanisms targeting various factors and diverse pathways that might cause a positive energy balance [15]. During the last decades, some anti-obesity drugs have been used to treat morbid obesity; however, most of these have been removed from the market owing to serious longterm side effects, particularly cardiovascular-related issues [16].…”
Section: Introductionmentioning
confidence: 99%
“…Orlistat, used as a positive control, is only one drug for long-term treatment of obesity. But the weight-loss effect of Orlistat is mild [ 29 , 30 ]. In the present study, Orlistat did not affect the body weight and white adipose tissue weight in HFD-induced obese mice.…”
Section: Discussionmentioning
confidence: 99%